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Abstract 
Background: Thalassemia and a bnormal hemoglobin are the most common genetic disorders and are 
considered health Prpblems in many developing countries. Beta-Thalassemia major is the most familiar type, in 
which the beta-globin chain synthesis is impaired. 
Objective: The aim of this study is to evaluate a new recent  member of the IL-1 super family of cytokines 
interleukin-33(IL-33) levels in serum that has a crucial rolein signaling cellular damage and infection diseases 
and in order to evaluate its utility as a clinical biochemical parameter in Beta-Thalassemia Major disease.  
Methods: The present study was conducted on 40 subjects which divided in to 2 groups. First group includes 20 
healthy individuals as control group . Second group includes 20 children with Beta-Thalassemia Major as 
patient group . All subjects attending Ibn-Al-Baladi hospital, and were (8-14) years old. Parameters 
measured in the sera of patient and healthy groups were interleukin-33 (IL-33), Iron and immunoglobulins 
(IgG,IgM,IgA) concentration, while (Hb) and fetus hemoglobin (HbF%) were determined in whold blood as 
diagnostic parameters in children with Beta-Thalassemia Major patient group and control group.  
Results: A recent member of super family cytokines Interterleukin-33(IL-33) was determined in serum of Beta-
Thalassemia Major Patients. Higher significant elevation was found when compared with healthy control. 
Conclusion: From this study a conclusion was drawn, that evaluation of concentration of a new superfamily 
cytokines (IL-33) could be considered as clinical biochemical parameter in Beta-Thalassemia Major in Iraqi 
children patients. Also this study may demonstrated a relation between increased IL-33 levels and increased 
immunoglobulins and Iron overload. 
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Introduction: 
Beta-Thalassemias are a group of hereditary blood disorders characterized by a nomalies in the synthesis of the 
beta chain of hemoglobin molecule resulting in variable phenotypes ranging from sever anemia to clinically 
asymptomatic individuals (1). Depletion or impaired synthesis of Beta-globins chain causes an imbalanced 
production of alpha chains, which converts hemoglobin from a normal oxygen transporting function into toxic 
inclusion bodies causing peripheral erythrocyte hemolysis (2,3). Immunoglobulins are glycoprotein molecules 
which are synthesized in response to a foreigen substance called antigen and immunglobulins function as 
antibodies (4). Thalassemia Major entails arisk of Iron overload and multi-organ involvement (5). The goal of 
iron chelation therapy is to reduce the body burden of iron, especially iron with labile compartments in the 
plasma, nontransferrin-bound (NTBI) as wellas in varions cells within the body. 
Removing iron in these pools will minimize the production of reactive oxygen species, thus reducing damage to 
internal organs such as the liver and heart resulting in reduced morbidity and impoved survival (6). 
Interleukins are a subset of a larger group of cellular messenger molecules called cytokines which are 
modulators of celluar behavior. Interleukin-33 (IL-33) is anew member of IL-1 super family that is expressed by 
many cell types following pro-inflammatory stimulation and thought to be released on cell lysis (7). Interleukins 
are secreted rapidly and briefly, in response to astimulus, such as infectious agent. Once an interleukin has been 
produced, it transports to its target cell and binds to it via areceptor molecule on the cells' surface. This 
interaction triggers a cascade of signals within the target cell that finally change the cell' behavior (8). 
Interleukins regulate immune responses (9). IL-33 can function both as a traditional cytokine and as anuclear 
factor regulating gene transcription. IL-33 mediates its bioloyical effects via interaction with the receptors 
interleukin 1 receptor- like 1(Il-IR IL-1) ST2 and IL-1 receptor accessory protein (IL-1RACP), both of which are 
widely expressed, particularly by innate immune cells and T helper 2 (Th 2) cells. IL-33 strongly stimulatesTh 2 
cytokine production from these cells and promte the pathogemsis of Th 2- related diseases such as asthma, 
Rheumatoid. Arthritis (10,11). Interleukin 33/ST 2 may be a dual function cytokine with both extracellular and 
intracellular signaling damage and infection diseases a property it shares IL-α. IL-33 influences the various cell 
types that express ST2 (12,13). 
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Patients and Methods:  
Forty subjects enrolled in this study which divided into 2 groups. First group consist of 20 healthy individuals as 
control group (G1) Second group consist of 20 subjects of Iraqi children with Beta-thalassemia Major as patient 
group (G2) treated by Iron chelators. The age of all studied groups were range from (8-14) years old.    
Veinous blood samples of (6 ml) were obtained from all subjects enrolled in this study divided into two portions: 
The first portion of (2 ml) was transferred into plain tube containing (EDTA) to obtain whole blood. The second 
portion of (4 ml) was transferred into plain tubes left to clot at room temperature for 15 min. Then centrifuged at 
3500 rpm for 10 min to separate the serum, and frozen till used .  
Interleukin-33 (IL-33) determinations:-                                            
Interleukin-33 (IL-33) has been determined using enzyme linked fluorescent assay (ELISA) technique using the 
manufacture instruction as supplied with kit from Ray Bio (R).  
Serum Immunoglobulins determinations:- 
Immunoglobulins (IgG, IgM, IgA) have been determined by a ready kit purchased from (parszmum company), 
Iran. The method depend on the turbidometric test which theimmunoglobulins form a complex with antibodies in 
solution which the absorbance read by spectrophotometer (14). 
Serum iron determination:- 
Iron concentration has been measured by Colorimetric method (15). 
Whole Blood Hemoglobin (Hb) determinations:- 
Hemoglobin level has been measured using the method of cyanomethemoglobin using Drabkin's reagent of 
commercially available kit (16). 
Whole Blood Fetus Hemoglobin (HbF%) determinations:- 
HbF has been detected on Hb electrophoresis on cellulose acetate membrane method (17). 
Statistical analysis :- 
The results were expressed as Mean  SD. 
Student-test was used to show the difference between group variation was considered significant when P-Values 
are  
Results:- Table (1) shows the levels of IL-33 concentration are (214.46 88.9 Pg/ml) , (40.47 58.7 Pg/ml) in 
sera of paticnts and control respectively. 
This table shows significant increase in children patients compared with the healthy control was for IL-33 and 
also significant increase in immunoglobulins (IgG, IgM, IgA) and Iron concentration. Table (2) shows the levels 
of hemoglobin (Hb) and HbF% which revealed a significant decrease in Hb levels in patients (5.32 0.76) 
compared with control group (10.34 0.85), while this table shows a significant increase in fetus hemoglobin 
HbF% in patients (40.13 11.28) compared with healthy control group (0.18 0.01). 
Discussion : 
    The results of the present study showed the serum of IL-33 level was significantly higher in children with 
Beta-Thalassemia major patients than in healthy control. No data in the literature was found concerning the level 
of lL-33 in such patients. Il-33 has been shown to signal through the ST2 (18,19). And to drive production of 
cytokines, both pro-inflammatory and T helper type 2 (Th 2) associated cytokines and chemokines in mast cells 
(20). Also there is strong evidence for a role of IL-33 and lymphocytes in regulating T helper type 2 (Th2) 
cytokines (21). Hence its ST2, which is a decoy receptor of IL-33, expressed strongly on Th2 cells (22,23). IL-33 
stimulates the production of IL-5 and IL-1B in these cells when IL-33 is administered to mice, increased levels 
of IgE and Th2 cytokines ensure (23). Moreover IL-33 is the most recently discovered member of the IL-1family 
which exhibits structural similarity to IL-18 (24). The results of the present study showed the serum levels of 
immunoglobulins were significantly higher in children with Beta-Thalassemia Major (BTM) than in healthy 
control. 
This finding suggest that the defence strategies of the body are collectively known as immunity, which mediated 
by a specialized group of proteins known as immunoglobulins or antibodies that have protective function and 
mediate immunity (25). Iron over load was suggested by some investigators as an important contributing factor 
in altering the immune parameters in thalassemia patients (26). And that study agreed with the result of the 
present study which showed the serum level of Iron was significantly higher in children with (BTM) patients 
than in healthy control. These findings also agreed with a no tier study which has been suggested that iron 
overload causes migration of T helper type 2 (Th2) cells to the gut and lymph nodes and results in an elevated 
immunoglobulins levels in Beta-Thalassemia major patients compared with healthy control (27). Also the results 
of the present study showed the levels of diagnostic parameters of (BTM) which were hemoglobin (Hb) and 
fetus hemoglobin (HbF%). The results revealed a significant decrease in Hb level in patients group compared 
with control group and this result suggest that in (BTM) patients there is an imbalance of globin chain synthesis 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.4, No.8, 2014 
 
93 
leads to red blood cells damage resulting in destruction of R.B.C in the bone marrow and peripheral circulation 
(hemolysis) (28). 
But the result of this study revealed a significant increase in fetus hemoglobin (HbF%) in children with (BTM) 
patients compared with control group. That is due to (HbF%) distribution rather than the occasional occurrence 
seen with other diseases or in specific fetal cells (28). Elevated (HbF%) level causes membrane damage of the 
fetal cells leading to premature R.B.C destruction and bone marrow production of abnormal cells (29).  
Conclusions: 
From the present study, a conclusion can be drawn, that evaluation of concentration of a recent super family 
cytokines IL-33 could be considered as a clinical biochemical parameter in Beta-Thalassemic major (BTM) 
children patients in Iraq. The increasing IL-33 levels may reflect the relation with the increased serum 
immunoglobulins levels and iron overload. These findings may indicate that IL-33 plays an important role in 
natural immunity and molecular cytogentic diseases such as Beta-Thalassemia Major (BTM), which may 
influence on immunoglobulins production and iron overload. This finding support that IL-33 stimulates the 
production of other interleukins such as IL-5 and IL-1B in T helper type 2 (Th2) cells in Iraqi children patients 
with Beta-Thalassemia Major. 
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Table (1):- The Concentration of (Mean SD) for IL-33, Immunoglobulins and Iron level in patient and control 
groups  
 
 
P value 
Patients(G2) 
n=20 
Mean ± SD 
Controls(G1) 
n= 20 
Mean ± SD 
Groups 
 
parameters 
P ≤ 0.05 214.46 ± 88.9 40.47 ± 58.7 IL-33 Pg/ml 
P ≤ 0.05 607.6 ± 15.04 401.6 ± 7.6 IgG mg/dl 
P ≤ 0.05 88 ± 2.99 48.24 ± 1.22 IgM mg/dl 
P ≤ 0.05 96.64 ± 2.99 67.44 ± 2.02 IgA mg/dl 
P ≤ 0.05 22.49 ± 5.80 10.38 ± 3.10 Iron M mde/dl 
 
 
Table (2):- The Concentration of (Mean SD) for Hemoglobin& fetus hemoglobin levels in patient and control 
groups  
 
P value 
Patients(G2) 
n=20 
Mean ± SD 
Controls 
n= 20 
Mean ± SD 
Groups 
Diagnostic parameters 
P ≤ 0.05 5-32± 0.76 10.34 ± 0.85 Hemoglobin (Hb) g/dl 
P ≤ 0.05 40.13 ± 11.28 0.18 ± 0.01 Fetus hemoglobin (HbF%) 
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